SIRT2 Inhibition promotes microglia LC3-associated phagocytosis via NRF2/CD36 after the experimental subarachnoid hemorrhage Authors: Bin Sheng, Xiangxin Chen, Tao tao, Jiaqing Sun, Wei Li, Lingyun Wu, Zheng Peng, Xiaojian Li, Zhengxu Zhou, Qian Yu, Yeping Ling, Prativa Sherchan, Jerry J Flores, Jiping Tang, Lei Huang, Chunhua Hang, John H Zhang Published: 2025 ABSTRACT AbstractBackgroundSubarachnoid hemorrhage (SAH) results in the accumulation of blood in the subarachnoid space, which can trigger inflammatory responses and oxidative damage, thereby exacerbating secondary brain injury. Microglia play a critical role in clearing hematomas and cellular debris during pathological recovery. This study aimed to investigate the regulatory role of SIRT2 in phagocytic function and its potential mechanisms.MethodsThe SAH model of endovascular perforation in Sprague-Dawley (SD) rats and in vitro model of primary microglia culture with Oxygenated hemoglobin (OxyHb) stimulation were used. Flow cytometry, Western blot, immunofluorescence, ELISA were used to detect the microglial phagocytic ability, expressions of SRIT2 and LC3-associated phagocytosis (LAP)-related proteins. Molecular docking, and immunoprecipitation were used to explore the underlying mechanism of the SIRT2/NRF2/CD36 signaling pathway. Behavioral experiments were conducted to evaluate changes in neurological function.ResultsWithin 24 h after SAH, the expression of SIRT2 in brain and microglia was significantly increased, while the phagocytic ability and the expression of LAP-related proteins Rubicon, NOX2 were decreased. After inhibiting SIRT2, microglial LAP function was enhanced and the phagocytic index was increased. Mechanistically, SIRT2 inhibited NRF2 nuclear translocation by deacetylation, thereby downregulating CD36 expression and suppressing microglia LAP. ML385 reversed the enhancement of LAP and the improvement in neurological function induced by SIRT2 inhibition.ConclusionSIRT2 suppresses microglial LAP by deacetylating NRF2, thereby impairing its nuclear translocation and reducing transcriptional expression of CD36 subsequently. Inhibiting SIRT2 may effectively enhance microglial LAP function via activating NRF2/CD36 pathway, promoting blood clearance and improving neurological prognosis after SAH.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12974-025-03623-z.Keywords: Subarachnoid hemorrhage, SIRT2, LAP, Phagocytosis, Microglia Introduction Subarachnoid hemorrhage (SAH) is a common and severe cerebrovascular disease, accounting for approximately 5% of all strokes, and is associated with high rates of mortality and disability. Its pathological process can be divided into primary brain injury and subsequent secondary brain injury (SBI) [1, 2]. In SBI, pathological processes induced by blood degradation products, such as neuroinflammatory responses, oxidative stress, and neuronal apoptosis are considered to be the pivotal factors in determining the prognosis of patients [3, 4]. Numerous studies have shown that rapid and effective clearance of blood components and cellular debris after SAH is critical for alleviating neurotoxicity, suppressing inflammation, and promoting tissue repair. Central immune cells, especially microglia, play an important phagocytic function in clearing hematomas and cellular debris [5, 6]. In our previous study, the decreased phagocytic ability of microglia was found within 24 h after SAH [7]. Therefore, elucidating the molecular mechanisms underlying intrinsic microglial phagocytic regulation is of great significance for identifying new therapeutic target to improve secondary brain injury after SAH. Sirtuin 2 (SIRT2), a member of the NAD⁺-dependent deacetylase family, is primarily localized in the cytoplasm and widely participates in the processes of oxidative stress, cell cycle regulation, and neurodegenerative diseases [8, 9]. In the Central Nervous System (CNS), SIRT2 has been implicated in regulating neuroinflammation and apoptosis [10]. Our previous study [11] have found that inhibiting SIRT2 can improve neurological function by promoting mitophagy in SAH mice. However, whether SIRT2 is involved in regulating microglial phagocytic function after SAH and its related mechanisms has not been fully clarified. LC3-associated phagocytosis (LAP) is a new non-canonical form of autophagy that exists at the intersection of phagocytosis and autophagy pathways. It depends on autophagy component LC3 assembly but does not require classic autophagy core proteins such as ULK1. LAP has high efficiency advantages in processing “bulky” substances such as bacteria, cell debris and bleeding products [12–14]. Studies have demonstrated that nuclear factor erythroid 2–related factor 2 (NRF2) activation enhances phagocytic activity in both macrophages and microglia, particularly in the process of LAP [15]. Notably, NRF2 has been reported that it can affect macrophage phagocytosis of oxidants and apoptotic cells by regulating the transcriptional activity of CD36 [16]. CD36, as a transmembrane receptor protein associated with phagocytosis, can recognize a variety of “eat-me” signals, such as oxidized low-density lipoprotein (oxLDL) and phosphatidylserine (PS) on the surface of apoptotic cells, and plays a key role in regulating the phagocytic function of macrophages and microglia [17–19]. However, whether there is a functional interaction between NRF2 and CD36 in SAH, and whether they are involved in the process of microglial clearance of blood components, remains to be explored [16, 17]. Collectively, the current study is based on the hypothesis that SIRT2 inhibition promotes LC3-associated phagocytic ability of microglia by NRF2/CD36 signal pathway after SAH. This study aims to systematically investigate the regulatory role of the SIRT2/NRF2/CD36 signaling pathway in autophagy associated microglial phagocytosis using both in vivo and in vitro models of SAH, with the goal of elucidating its underlying molecular mechanisms and providing novel theoretical evidence and therapeutic targets for immune intervention after SAH. Materials and methods Animals All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Loma Linda University and adhered to the National Institutes of Health’s (NIH) Guide for the Care and Use of Animals in Neuroscience Research and the ARRIVE guidelines. Adult Sprague-Dawley (SD) male rats (weighing 270–320 g) and 1-day-old rat pups (Envigo, Indianapolis, IN) were housed in a standard laboratory environment with controlled temperature and humidity according to animal husbandry standards, a 12-h light/dark cycle, and free access to water and food. Experimental design This study was divided into 6 experimental groups, as illustrated in Fig. S1. Experiment 1: Time course, cellular co-localization and short-term outcomes in rat model of SAH; Experiment 2–5: Mechanistic experiments to elucidate the proposed SIRT2/NRF2/CD36 signaling pathway underlying LAP in primary microglia in an in vitro SAH model.; Experiment 6: Long-term outcomes and validation of downstream NRF2 in rat model of SAH. For in vivo experiments, animals were randomly assigned to separate groups. In the event of mortality, deceased animals were replaced to maintain a sample size of 6 per group for short-term outcomes and 10 per group for long-term outcomes. In vitro experiments were partially performed at Nanjing Drum Tower Hospital. All procedures were approved by IACUC of Nanjing Drum Tower Hospital of Nanjing University. Each condition was tested in triplicate. Researchers involved in surgery, cell culture, data collection, or analysis were blinded to group assignments to minimize bias. Rat model of SAH The rat model of endovascular perforation was induced as previously described [20]. Briefly, isoflurane (3% induction and 1.5% maintenance) anesthetized rats underwent endotracheal intubation and connected to a ventilator for small animals (TOPO dual mode ventilator, Kent Scientific Corporation) in the supine position. with the head was secured and the limbs and tail were restrained. The midline neck region was shaved and incised layer by layer to expose the trachea and the pulsating common carotid artery (CCA), and the CCA, external carotid artery (ECA), and internal carotid artery (ICA) were carefully separated. The ECA was electrocoagulated and a small oblique incision was made at its distal end. A 4 − 0 nylon suture with a rounded tip and pre-marked length was inserted through the ECA and advanced along the ICA toward the bifurcation of the middle cerebral artery (MCA). In the SAH group, the nylon suture was further advanced until a slight resistance was felt, then pushed forward an additional 1–2 mm to induce vessel perforation, followed by gradual withdrawal of the filament and cauterization of the ECA stump. The ligatures on the ICA and CCA were then released, and after confirming no bleeding, the incision was closed in layers and disinfected with povidone-iodine. Anesthesia was discontinued, and rats were transferred to a heating pad until full recovery. For the sham group, the procedure was identical, except the nylon filament was withdrawn immediately after encountering resistance without perforating the vessel. All animals were extubated and monitored in recovery cages until fully awake. Cell culture and SAH model in vitro Primary microglia were isolated according to our previously study [11]. Briefly, all cell culture tools, ice, and surgical instruments were sterilized in advance. Several 10 mm culture dishes were placed on ice and pre-cooled with sterile phosphate-buffered saline (PBS) and 75% ethanol. Neonatal rat pups within 24 h of birth were immersed in 75% ethanol for sterilization. After satisfactory disinfection, then killed the rats and got the brain tissues, then the meninges were carefully removed under the dissecting microscope, and only bilateral cortical tissues from the temporal lobes were retained for subsequent procedures. The cortical tissue was cut into 1 mm³ pieces using sterile scissors and digested in 0.25% Tryple at 37 °C for 10 min in cell incubator. The digestion was terminated while added equal DMEM. The cell suspension was gently triturated using a 1 mL pipette several times to dissociate the cells. After standing for 5 min, the supernatant was filtered through a 70 μm cell strainer into a 50 mL centrifuge tube to remove tissue debris. This step was repeated 4–5 times until only residual cells remained. The filtered suspension was centrifuged at 1,000 × g for 5 min, then supernatant was discarded, and the cell pellet was resuspended in DMEM and seeded into T75 culture dish. The dishes were incubated at 37 °C with 5% CO₂. The medium was changed on days 3 and 7. Microglia usually matured between days 10 and 14. Mature microglia were collected by gentle shaking for subsequent experiments. For the in vitro SAH model, as previous described [11], primary microglia were stimulated with 25 µmol/L of oxygenated hemoglobin (OxyHb, Hemoglobin bovine, H2500, Sigma). Drug administration SIRT2 inhibitor AK7 (MCE, USA) was dissolved in dimethyl sulfoxide (DMSO). In in vivo experiments, AK7 (10 mg/kg, 20 mg/kg, or 30 mg/kg) or NRF2 inhibitor ML385 were administered intranasally (I.N.) at 1 h after SAH in rats [20, 21]. Based on the short-term neurological functions, the optimal dose of AK7 was used for long-term outcomes and mechanistic studies was used. For long-term neurological functions, the same treatments were given once daily for 7 consecutive days after SAH. In vitro experiments, AK7 or ML385 was added to the culture medium at 1 h after OxyHb stimulation for mechanistic investigations. The optimal concentration of AK7 for mechanistic experiments was selected according to the results of cell variability. Brain water content Brain water content was measured at 24 h after SAH. First, PBS was perfused into the left ventricle of rats, and brain tissues were obtained, and the olfactory bulb, cerebellum, and brainstem were removed, leaving only the left and right cerebral hemispheres. The brain tissue weight at this point was the wet weight, which was then dried in an electric oven at 110 °C for 24 h and weighed again as the dry weight. The percentage of brain water content was calculated as ([Wet weight − Dry weight]/Wet weight) × 100%. Blood-brain barrier permeability Evans blue dye was used to assess the permeability of the blood–brain barrier (BBB). At 24 h after SAH, 5% Evans blue dye (E2129, 2%, 5 mL/Kg, Sigma Aldrich) was administered via tail vein injection until the dye was visibly distributed in the eyes, skin, and ears of the rats. One hour later, rats were perfused whole-body intracardiacly with pre-cooled PBS to clear the intravascular Evans blue dye and then obtained brain tissues. The brain samples were homogenized in 50% trichloroacetic acid (TCA). The homogenates were centrifuged at 1,000 × g for 15 min at room temperature. The resulting supernatant was mixed thoroughly with ethanol and TCA and incubated overnight at 4 °C. On the following day, the optical density (OD) in the supernatant was measured at 620 nm using a spectrophotometer. Results are expressed as micrograms of Evans blue dye per gram of brain tissue. Immunofluorescence staining The rats were euthanized at designated time points after modeling and perfused intracardially with PBS followed by 10% formalin. The brains were harvested and fixed in formalin for 24 h, then cryoprotected in 15% and 30% sucrose solutions sequentially for 3–4 days. After complete dehydration, the brains were embedded and frozen in Tissue-Tek OCT. Coronal slices (20 μm) were cut at 1.0–1.5 mm posterior to the bregma using a cryostat (Leica CM1900) and stored at − 80 °C for subsequent experiments. The slides were permeabilized, blocked, and incubated with primary antibodies overnight at 4°C. The following antibodies were listed as following: rabbit anti-SIRT2, goat anti-Iba1 (all 1:200, Abcam, USA), rabbit anti-NeuN, rabbit anti-GFAP (all 1:200, CST, USA). After washing 3 times with PBS, the tissue samples were incubated with the following secondary antibodies for 1 h, Alexa Fluor 488 goat anti-rabbit IgG or Alexa Fluor 594 goat anti-mouse IgG, Alexa Fluor 488 donkey anti-goat IgG or Alexa Fluor 594 donkey anti-rabbit IgG (all 1:400, Invitrogen, USA). After washing 3 times with PBS, slides were mounted with DAPI (4’, 6-Diamidino-2-Phenylindole, Dihydrochloride, Jackson ImmunoResearch, West Grove, USA) and fixed with coverslips for fluorescence photography. the images were captured with a fluorescence microscope (Leica, DMI8) and analyzed by the software of Image J. In the vitro experiment, the primary microglia were seeded into confocal dishes at 70% confluency. For the pHrodo staining, cells were incubated with diluted pHrodo (1:10,000, Thermo Fisher) for 30 min in the dark at 37 °C. After removing the medium, cells were washed 3 times with PBS and fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100, and blocked with quick immunofluorescence blocking solution. Primary antibodies were diluted 1:100 and incubated overnight at 4 °C. The antibodies were used as following: rabbit anti-LC3 (1:200, CST, USA), rabbit anti-NRF2 (1:200, Proteintech, China). After washing 3 times with PBS, cells were incubated with secondary antibodies in the dark for 1 h. The secondary antibodies used were Alexa Fluor 488 donkey anti-rabbit IgG (1:400, Invitrogen, USA). After washing 3 times with PBS, cells were mounted with DAPI. The images were acquired using a laser scanning confocal microscope (Leica DMI8), and analyzed with Image J software. Cell viability assay and cytotoxicity assay To evaluate the cytotoxicity and optimal concentration of AK7 in microglia, cell viability was assessed using the Cell Counting Kit-8 (CCK-8, Dojindo, Japan) according to the manufacturer’s instruction. Microglia were seeded into 96-well plates at a density of 5 × 10³ cells per well in DMEM, then incubated at 37 °C in a 5% CO₂ incubator for 24 h. The medium was replaced with serum-free DMEM containing different concentrations of AK7 (5µM, 10µM, or 20 µM) or ML385 (1µM, 2µM, or 4 µM) with three replicate wells for each concentration. After 24 h of incubation, 10 µL of CCK-8 was added to each well and incubated for 1 h. The absorbance at 450 nm (OD450) was measured using a microplate reader. These results were used to determine the non-toxic and effective concentration of AK7 or ML385 for subsequent functional experiments. Meanwhile, lactate dehydrogenase (LDH) release was measured using an LDH Cytotoxicity Assay Kit according to the manufacturer’s instructions. LDH levels in the cell culture supernatant were used as an index of cytotoxicity. All experiments were independently repeated three times. Fluoro-Jade C(FJC) staining Neuronal degeneration was assessed using the Fluoro-Jade C (FJC) staining kit (TR-100-FJC, Biosensis, Australia) according to the manufacturer’s instruction. Briefly, frozen brain slices obtained from SAH rats were air-dried in a drying oven for 15 min. The slides were then incubated in a solution of 1% NaOH in 80% ethanol for 5 min to remove lipids, followed by sequential incubation in 70% ethanol and PBS for 2 min. To reduce background fluorescence, the slides were transferred to 0.06% KMnO₄ solution and shaken for 10 min, then washed twice with PBS. Next, the slices were incubated in the dark with 0.0001% FJC solution (prepared in 0.1% acetic acid) for 10 min. After staining, the slides were washed three times with PBS, transparentized in xylene for 2 min, and covered with a coverslip. The degenerated neurons were observed under a fluorescence microscope (488 nm). Flow cytometry (FCM) Flow cytometry was used to determine the phagocytic index in cultured primary microglial, which was measured using pHrodo. First, the medium in the wells was aspirated, washed twice with PBS, and pHrodo™ Red (#35361, ThermoFisher) was dissolved in serum-free DMEM at a dilution of 1:10,000 and incubated without light in a 37 °C incubator for 30 min. The DMEM was aspirated, washed three times with PBS, and the cells were digested with 0.25% Trypsin for 5 min, terminated with DMEM. Microglia were gently pipetted to detach from the bottom of the wells. After collection, the cells were centrifuged at 3,000 x g for 5 min. The supernatant was discarded, the cells were resuspended in PBS, and centrifuged again at 1,000 x g for 5 min. Changes in the phagocytic index in each group were measured using a flow cytometer (C6+, BD Accuri™, China), and analyzed using FlowJo software. RNA extraction and quantitative real-time PCR Total RNA was extracted from cells using the Total RNA Extraction Reagent (R401-01, Vazyme, China). Subsequently, 500 ng of total RNA was reverse transcribed into cDNA using the HiScript II 1 st Strand cDNA Synthesis Kit (R211-01, Vazyme, China). Quantitative real-time PCR (qRT-PCR) was performed using the HiScript II Q RT SuperMix (R222-01, Vazyme, China) under the following cycling conditions: pre-denaturation at 94 °C for 30 s, denaturation at 94 °C for 5 s, annealing at 60 °C for 30 s, for a total of 40 cycles. GAPDH was used as the internal control for normalization and the GAPDH (2−ΔΔCt) was applied to calculate relative mRNA expression levels (all mRNAs were listed in Supplemental Table S1). All experiments were conducted in triplicate. Western blot Total and nuclear proteins were extracted using RIPA lysis buffer (sc-24,948, Santa Cruz Biotechnology, USA) and protease inhibitors, as previously described [11]. Equal amounts of protein were were separated by SDS–polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5–12.5% gels and transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, USA). The membranes were blocked with 5% non-fat milk for 1 h, washed three times with TBST for 10 min, and incubated overnight at 4 ℃ with primary antibodies (see Supplementary Table S2 for all primary antibodies). After washing three times with TBST, the corresponding secondary antibodies were added and incubated for 1 h at room temperature. The protein immunoblot images were visualized using the Bio-Rad image system (Versa Doc, model 4000) and Tanon 5260 Multi (Tanon, Shanghai) and quantified using Image J software (NIH, USA). All experiments were performed in triplicate. Enzyme linked immunosorbent assay (ELISA) After the SAH model in vitro was established, the levels of inflammatory cytokines IL-1β, IL-6, and TNF-α were quantified using ELISA kits (ab255730, ab234570, and ab236712; Abcam, USA) according to the manufacturer’s instructions. Briefly, 100 µL of standard solution was added to each well, followed by incubation at 37 °C for 2 h. The liquid was then removed from each well, and 100 µL of biotinylated antibody solution was added and incubated at 37 °C for 1 h. After washing three times with PBS, 100 µL of HRP–avidin conjugate was added and incubated at 37 °C for 1 h. The wells were washed again with PBS three times. Subsequently, 90 µL of TMB substrate solution was added to each well and incubated at 37 °C for 30 min. Finally, 50 µL of stop solution was added to each well, and the absorbance was measured at 450 nm using a microplate reader after 5 min. Molecular docking See in supplemental material Nuclear and cytoplasmic protein extraction Nuclear and cytoplasmic proteins were extracted using a Nuclear and Cytoplasmic Protein Extraction Kit (P0027, Beyotime, China). Briefly, after washing the cells with PBS, they were collected by centrifugation and resuspended in cytoplasmic protein extraction reagent A containing PMSF. The suspension was vortexed at high speed for 5–10 s, followed by incubation on ice for 10–15 min. Then, cytoplasmic protein extraction reagent B was added, and the mixture was vortexed at maximum speed for another 5–10 s and kept on ice for 1 min. After a brief vortex for 5 s, the samples were centrifuged at 12,000–16,000 × g at 4 °C for 5 min. The supernatant was collected as the cytoplasmic protein fraction. For the precipitate obtained in the previous step, we added nuclear protein extraction reagent containing PMSF, vortexed vigorously for 15–30 s, and intermittently incubated on ice for 30 min. Finally, the samples were centrifuged at 12,000–16,000 × g at 4 °C for 10 min, and the supernatant was collected as the nuclear protein fraction. The extracted proteins were used for subsequent experiments. Co-immunoprecipitation (Co-IP) First, cells from each group were collected, and the protein was quantified to 2 mg/ml. For each sample, two Eppendorf (EP) tubes were used for the immunoprecipitation (IP) group and IgG group, while a third tube was reserved for the input group. Protein A/G plus beads (20 µL, Santa Cruz Biotechnology, USA) were prepared in lysis buffer and centrifuged to remove the supernatant. The supernatants were then transferred to new EP tubes. 1 µg of antibody or IgG was added into the IP group and IgG group, respectively, and the mixtures were incubated overnight at 4 °C with rotation. On the second day, the beads were washed and resuspended, then added to the samples and rotated for 2 h. The beads were collected by centrifugation and washed three times with PBS. Finally, 1× SDS loading buffer was added to resuspend the beads, followed by boiling for 5 min in a metal bath. After centrifugation at 13,000 × g for 1 min, the supernatants were collected and subjected to western blot. Lentiviral transfection We performed recombinant lentivirus infection experiments to construct Rubicon knockdown genes. The recombinant lentiviral vector was purchased from Genechem (China). For lentiviral transduction, cells were seeded at a density of 5 × 10⁴/well in a 96-well plate 18–24 h before infection. When the cell density reached 70–80% after 24 h, transduction was initiated. After replacing the medium, an appropriate amount of lentiviral suspension was added to each well. Cells were incubated at 37 °C for an additional 24–48 h, we added an appropriate amount of puromycin for screening. Once the density reached 80–90%, cells were harvested for q-PCR and Western blot analyses to assess transduction efficiency. Successfully transduced cells were used for subsequent experimental procedures. Tandem mass tag (TMT) protein quantitative sequencing Microglia from the SIRT2 knockdown group and the control group were subjected to TMT based quantitative proteomic analysis. After lysis and quantification of protein samples, equal amounts of protein from each group were reduced with dithiothreitol (DTT) and alkylated with iodoacetamide (IAA). The proteins were then digested with trypsin to generate peptides. The resulting peptides were desalted, dried, and labeled with TMT reagents, assigning distinct TMT tags to different samples. After labeling, the samples were pooled and subjected to high-pH reverse-phase liquid chromatography for fractionation. The resulting peptide fractions were analyzed using nano-liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Mass spectrometry was performed in data-dependent acquisition (DDA) mode, and peptides were identified and quantified using high-resolution MS data. The raw data were processed using Proteome Discoverer or similar software to search against a protein database. Proteins were identified with a false discovery rate (FDR) threshold of 1%, and performed TMT-tag quantification. Quantified protein data were normalized and statistically analyzed to identify differentially expressed proteins, and functional annotation and pathway enrichment analysis were performed in combination with GO and KEGG. JASPAR analysis In order to predict the binding sites in the promoter region of the gene that the target protein may regulate, the promoter sequence of the target gene is first obtained. Download the sequence within 2000 bp upstream of the target gene from the Genome Browser database to serve as the promoter region. Then, log in to the JASPAR database (https://jaspar.genereg.net/), enter the above FASTA format sequence and the transcription factor being studied, select the corresponding species and set the corresponding score threshold (≥ 80%) to improve prediction accuracy. Transmission electron microscopy (TEM) Cells were collected by centrifugation and fixed in pre-cooled 4 °C electron microscopy fixative. After fixation for 15 min, the cells were gently scraped and centrifuged at 3,000 × g for 10 min to collect the cell pellet (approximately the size of half a mung bean). The pellets were placed in 1% osmium tetroxide and dehydrated through a graded ethanol series. They were then treated with propylene oxide and infiltrated with resin overnight at 25 °C. After embedding, the resin blocks were polymerized at 60 °C for 48 h. Regions of interest were re-embedded at the tip of the resin blocks, and ultrathin slides (60–80 nm) were obtained using an ultramicrotome. The slides were collected and examined using a Hitachi TEM (HT7800, HITACHI) at 80 kV. Neurological function assessment Short-term neurological function assessment The modified Garcia score was used to evaluate neurological deficits [22]. The Garcia test is an 18-point scoring system consisting of six items: spontaneous activity, symmetry in limb movement, forelimb outstretching, climbing, body proprioception, and response to vibrissae touch. The higher scores indicating better neurological function. Long-term neurological function assessment Rotarod test The rotarod test was performed on days 7, 14, and 21 after SAH to assess motor coordination and balance. The initial rotation speed was set at 5 or 10 revolutions per minute (RPM), increasing by 2 RPM every 5 s. Each animal was allowed to run five times per testing day. The average duration of rats remained on the rotating rod was recorded. A photo beam circuit recorded the time rats could stay on the accelerating. rotating cylinder. Morris water maze test The Morris water maze test was conducted from days 23 to 28 post-SAH to evaluate spatial learning capacity and memory. Swimming path, escape latency, and distance to the hidden platform were recorded individually from days 23 to 27 post-SAH. On day 28, the platform was removed and a 60 s probe trial was conducted to assess swimming speed and the time spent in the target quadrant. All parameters were recorded using a computerized tracking system (SMART-2000, Noldus Ethovision; Noldus, Tacoma, USA). Nissl staining Nissl staining was performed to assess the number of surviving neurons in the hippocampal CA1 at day 25 as described previously. The brain slices were first fixed with 4% PFA for 10 min, washed twice with PBS, and then stained with Nissl staining solution (C0117; Beyotime) for 3 min. Subsequently, the slices were washed with PBS and 95% ethanol, washed again with 95% ethanol, and transparentized with xylene for 5 min before finally covering with neutral resin. Observations were recorded under a microscope, and statistical analysis was performed using Image J. Statistical analysis Statistical analyses were performed using SPSS 22.0 software (IBM, USA) and GraphPad Prism10.0 (GraphPad Software, USA). Data were first tested for normality using the Kolmogorov–Smirnov test. Normally distributed data are presented as mean ± standard deviation (SD), while non-normally distributed data are expressed as median values. Student’s t-test was used to compare differences between two groups, and one-way analysis of variance (ANOVA) was applied for comparisons among multiple groups. The p-value < 0.05 was considered statistically significant. Results 1. Mortality and SAH grade after SAH in rats A total of 140 rats were used, of which 28 rats underwent sham surgery, and 96 rats underwent SAH induction (Supplemental Table S3). No rats died in the sham group. While the overall mortality rate of SAH rats was 14.29% (16/112), the mortality was not significantly different among all SAH groups. There was no statistically difference in SAH grade among all SAH groups. 2. Time course of brain SIRT2 expressions and effects of SIRT2 inhibition after SAH in rats The expressions of SIRT2 at 6 h, 12 h, 24 h, 48 h, and 72 h were assessed by western blotting. The results showed that the SIRT2 expression was significantly increasing from 6 h with the highest expression level at 24 h (Fig. 1A-B, P < 0.01). Therefore, we chose to conduct follow-up studies 24 h after SAH. To further clarify which neural cells SIRT2 plays a role after SAH, we performed immunofluorescence staining. The results showed that SIRT2 was predominantly expressed in microglia, with limited expressions in neurons and almost absence in astrocytes (Fig. 1C-G, P < 0.01). SIRT2 was also expressed in oligodendrocytes, but was rarely detected in endothelial cells (Fig. S2). Expression of SIRT2 and its prognostic impact after SAH in rats. A-B, Western blot and quantifications of SIRT2 level at different time courses. C-E, Representative images show in the temporal cortex stained with antibodies to SIRT2 and Iba1 (C), NeuN (D), or GFAP (E) at 24 h post-SAH. F, The mean fluorescence intensity (MFI) of SIRT2 immunoreactivity. G, Percentages of Iba1+SIRT2+, NeuN+SIRT2+and GFAP+SIRT2+ in the temporal cortex of each group. H, Neurological score, I, brain water content (J) and Evan’s blue in different (Sham, SAH, Vehicle and AK7) groups at 24 h after SAH. K-L, FJC staining in the cortex with quantification. Scale bar: 50 μm. ** P < 0.01, *** P < 0.001, **** P < 0.0001 SIRT2-specific inhibitor AK7 treatment alleviated the short-term neurological deficits in SAH rats with optimal dose of 20 mg/kg (Fig. S3). The treatment also significant reduced brain edema, Evans blue extravasation, and FJC staining positive degenerating neurons in SAH rats (Fig. 1H–L, P < 0.01). 3. The change of microglia phagocytic ability after SAH in vitro The level of phagocytic index by flow cytometry was used to evaluate the changes of microglial phagocytic ability at 6 h, 12 h, 24 h, 48 h and 72 h after SAH. The results showed that in the early stage of SAH (< 24 h), the phagocytic ability of microglia started decreasing from 6 h to 24 h, and it recovered to the level of normal control at 48 h and 72 h (Fig. 2A-B, P < 0.01). In order to explore whether this microglia phaticity ability is related to LC3-associated phagocytosis, we used western blot to detect the expression levels of LC3 phagocytosis-related proteins (Rubicon, NOX2, Beclin1). The results showed that the expression levels of Rubicon, NOX2, and Beclin1 were decreased at the similar time dependent pattern to changes of microglial phagocytic ability (Fig. 2C-F, P < 0.01). These results suggest that the LC3-associated phagocytic ability of microglia is decreased in the early stage (< 24 h) after SAH. Change of microglia phagocytosis after SAH. A-B, The change of phagocytic index and analysis at different time courses by pHrodo. C-F, Western blot and quantitative analysis of Rubicon, NOX2 and Beclin1 expressions at different time courses.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s., no significant 4. Inhibition of SIRT2 enhances microglia phagocytosis after SAH in vitro As previously mentioned, SIRT2 functions in microglia through LAP. To investigate the effect of SIRT2 on microglial phagocytosis, we established the SAH model in vitro and inhibited SIRT2 expression using the SIRT2 inhibitor AK7 with optimal dose of 10µM (Fig. S4). Western blot assay showed that AK7 significantly decreased SIRT2 level (Fig. 3A-B, P < 0.01) and increased the phagocytic index at 24 h after SAH, comparing with normal control and DMSO treatment (Fig. 3C-D, P < 0.05). In order to further investigate whether SIRT2 acts through LAP, the colocalization of LC3 and pHrodo was evaluated by immunofluorescence. Compared with the normal control group, the colocalization was decreased in the OxyHb and OxyHb + DMSO groups, but significantly improved by AK7 (Fig. 3E-F, P < 0.01). Western blot assay showed AK7 significantly increased expressions of LAP-associated protein levels including Rubicon, NOX2, Beclin1, and LC3 compared to that in the OxyHb control and DMSO groups (Fig. 3G-K, P < 0.01). These results suggest that inhibiting SIRT2 expression promotes LC3-associated phagocytic ability of microglia after SAH. SIRT2 inhibition promotes microglia phagocytosis. A-B, Western blot and quantitative analysis of SIRT2 expressions in microglia (Con, OxyHb, DMSO and AK7) groups. C-D,phagocytic index level and analysis by pHrodo. E-F,Immunofluorescence staining and quantitative analysis of LC3 and Phrodo in microglia. Scale bar: 10 μm. G-K, Western blot and quantitative analysis of Rubicon, NOX2, Beclin1 and LC3 A/B expressions. *P < 0.05,**P < 0.01,***P < 0.001, ****P < 0.0001 5. SIRT2/NRF2/CD36 signaling in microglial phagocytosis after SAH in vitro To further clarify the downstream signaling by which SIRT2 regulates microglial phagocytosis, we first constructed SIRT2 knockdown (SIRT2 KD) cells based on previous studies and performed protein quantitative sequencing [11]. As shown in Fig. 4 A, heatmap analysis of differentially expressed proteins between Con and SIRT2 KD revealed marked upregulation of canonical NRF2 target genes, including Hmox1 and Gclm. Simultaneously, the expressions of Kelch-like ECH-associated protein 1 (KEAP1), a protein regulating the activity of NRF2, was decreased, indicating that the NRF2 pathway was activated after SIRT2 knockdown. The molecular docking experiment was performed to explore the potential interaction between SIRT2 and NRF2, the results showed that SIRT2 and NRF2 could bind to each other. Since SIRT2 is a deacetylase, co-immunoprecipitation of acetylated proteins was performed. The results showed that SIRT2 modifies NRF2 through deacetylation, and that inhibition of SIRT2 increased NRF2 acetylation levels (Fig. 4D-G). As a transcription factor, NRF2 typically requires nuclear translocation to exert its transcriptional function. To verify whether NRF2 underwent nuclear translocation, we performed nuclear-cytoplasmic fractionation analysis. The results showed that NRF2 significantly translocated to the nucleus after SAH, and the expression was further enhanced after SIRT2 inhibition. Laser confocal microscopy also revealed similar results, showing a significant increase in NRF2 nuclear translocation after SAH (Fig. 4H-K). These results indicate that NRF2, as a downstream of SIRT2, regulates microglia phagocytosis after SAH through acetylation modification and nuclear translocation. SIRT2 deacetylates NRF2 and promotes its nuclear translocation in microglia. A-C, Heatmap analyses and q-PCR detects different NRF2 target genes in microglia (SIRT2 and SIRT2 KD) groups. D, Molecular docking shown the obvious interaction force between SIRT2 and NRF2. E-G, Co-immunoprecipitation and quantitative analysis of acetylated NRF2 in SIRT2 WT and KD microglia. H, Western blot and quantitative analysis of NRF2 in microglia (Con, OxyHb, DMSO and AK7) group with Cyto and nucleus. I-K, The co-localization of NRF2 and nucleus with laser confocal and analysis in Con group and OxyHb group of microglia. Scale bar: 10 μm. * P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s., no significant To investigate whether CD36 is associated with microglial phagocytosis through NRF2 after SAH, we first performed a prediction analysis using the JASPAR database, and the results showed that NRF2 has a binding site in the promoter region of CD36 (Fig. 5 A). In order to further confirm the signaling of SIRT2/NRF2/CD36, we used the NRF2 specific inhibitor ML385. We found that CD36 expression increased significantly after SIRT2 inhibition, while CD36 expression decreased after ML385 with the optimal dose of 2µM (Fig. S5) was administrated (Fig. 5D-E, P < 0.01). This result is consistent with the JASPAR result, indicating that NRF2 regulates CD36 expression in response to the SIRT2 inhibition. To functionally verify this finding, we also performed flow cytometry to detect the changes in pHrodo. The results showed that when SIRT2 was inhibited, the phagocytic ability of microglia increased, and this result was reversed after the addition of ML385 (Fig. 5B-C, P < 0.05). Consistent to phagocytic ability of microglia, ELISA results showed the similar pattern of changes in pro-inflammatory cytokines including TNF-α, IL-1β and IL-6 (Fig. 5F-H, P < 0.01). These results indicate that SIRT2 inhibits NRF2 activity and reduces its transcriptional activation of CD36, thereby impairing the microglia phagocytosis and increasing the release of pro-inflammatory cytokines. SIRT2 through NRF2/CD36 regulates microglial phagocytosis. A, JASPAR predict NRF2 bind to the promoter region of CD36. B-C, phagocytic index level and analysis by pHrodo in microglia (Con, OxyHb, DMSO, AK7 and AK7+ML385) groups. D-E, Western blot and quantitative analysis of CD36 expression. F-H, ELISA quantitative analysis of pro-inflammatory cytokines (TNF-α, IL-1β and IL-6) level in different groups.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 6. SIRT2 regulation and LC3-associated phagocytosis (LAP) pathway in microglial after SAH in vitro To further clarify the mechanism of SIRT2 on microglial phagocytosis, we accessed the expressions of key proteins related to canonical autophagy LAP. ULK1 is a representative protein of canonical autophagy, while Rubicon and NOX2 are key markers of the LAP pathway. LC3 is involved in both pathways. First, we constructed a Rubicon knockdown microglia (Fig. S6) to explore its role in SIRT2-mediated phagocytosis regulation. Western blot analysis revealed that SIRT2 inhibition significantly increased the expression of Rubicon and NOX2, while ULK1 expression remained unchanged, suggesting that SIRT2 has a minimal effect on canonical autophagy. While Rubicon was knocked down, the expression levels of Rubicon and NOX2 were significantly decreased, further supporting their roles in LAP. Notably, simultaneous inhibition of NRF2 resulted in a moderate recovery of Rubicon expression, suggesting that SIRT2 may regulate LAP through NRF2. Furthermore, the expression of LC3 was consistent with that of Rubicon, further supporting the involvement of SIRT2 in regulating LAP (Fig. 6A-F, P < 0.05). To further validate these findings, we performed immunofluorescence staining to examine the colocalization of pHrodo and LC3. Compared to the control group, the SIRT2 inhibition significantly improved the colocalization, which was reversed by NRF2 inhibition (Fig. 6G-H, P < 0.01). Meanwhile, the TEM also revealed similar results, in which SIRT2 inhibition significantly increased the number of LAPosomes with a single membrane structure characteristic of LAP, accompanied by a certain proportion of Rubicon particles surrounding the membrane. However, the number of LAPosomes decreased after NRF2 inhibition (Fig. 6I-J, P < 0.01). These results suggest that the SIRT2 regulation of microglia phagocytosis is mediated through the LAP pathway. SIRT2 via LAP inhibits phagocytosis in microglia.A-F,Western blot and quantitative analysis of Rubicon, ULK1, CD36, NOX2 and LC3 A/B expressions. G-H, The co-localization of LC3 and pHrodo with laser confocal and analysis indifferent groups of microglia. Scale bar: 10 μm. I-J, Representative TEM images of LAPosomes in microglia. (The black triangle refers to the single membrane structure characteristic of LAPosomes and star refers to the Rubicon particles). Scale bar: 3 μm (upper panels), 1 μm (lower panels). *P < 0.05 vs. Hb, #P < 0.05 vs. Hb+AK7, &P < 0.05 vs. Hb+shRNA, $P < 0.05 vs. Hb+AK7+shRNA, ☆P < 0.05 vs. Hb+AK7+ML385, ***P < 0.001,****P < 0.0001 7. SIRT2 inhibition on long-term outcomes and downstream NRF2 validation after SAH in rats To evaluate the effects of SIRT2 on long-term neurological function, Rotarod and Morris water maze tests were performed after SAH. The Rotarod test demonstrated that the latency to fall in the SAH + Vehicle group was significantly reduced in both 5 RPM and 10 RPM acceleration tests compared to the sham group at 1, 2, and 3 weeks after SAH. However, treatment with AK7 significantly prolonged the latency to fall. Notably, this latency was partially reversed when NRF2 inhibitor ML385 was co- administrated (Fig. 7A-B, P < 0.05). Inhibition of SIRT2 improves long-term neurological function after SAH. A-B, The falling latency of rotarod test (5RPM and 10 RPM) at 1, 2, and 3 weeks after SAH in rats. C-E,Escape latency and swimming distance of Morris water maze test on days 23 to 27 after SAH. F-G, Quantification of probe quadrant duration and swimming velocities. H-I, Representative images and neuronal quantifications of Nissl staining in CA1 hippocampal region. Scale bar: 200 μm (upper panels), 50 μm (lower panels). *P < 0.05, **P< 0.01, ***P < 0.001, ****P < 0.0001, n.s., no significant Morris water maze test at 4 weeks after SAH. Compared with the sham group, the SAH and vehicle group shown significantly impaired spatial memory and learning ability, with a longer escape latency from days 25 to 27 after SAH and a longer swimming distance 23 to 27 after SAH. While treatment with AK7 significantly shortened the escape latency from days 25 to 27, accompanied by a decrease in swimming distance from days 23 to 27 after SAH. In the probe trials, the Vehicle group rats spent less time in the probe quadrant compared to the sham group. AK7 treatment increased their quadrant duration. This benefit was also reversed in SAH rats cotreated with NRF2 inhibitor ML385 (Fig. 7C-E, P < 0.05). There has no significant difference in swimming velocity (Fig. 7 F, P > 0.05). Nissl staining showed that the number of CA1 surviving neurons in SAH group was significantly less compared to sham group. AK7 treatment preserved the number of CA1 surviving neurons, but this benefit was reversed by NRF2 inhibitor ML385 (Fig. 7H-I, P < 0.05). Discussion This study systematically elucidates the regulatory role of SIRT2 in microglial phagocytosis after SAH. The novel findings are (1) there were significantly increase of SIRT2 expressions in SAH rats, peaking at 24 h and primarily co-localized with microglia; (2) SIRT2 inhibition significantly improved short-term and long-term outcomes after SAH in rats. Its long-term cognitive benefit and neuronal protection were reversed by co-administration of a NRF2 inhibitor in SAH rats; (3) primary microglial culture showed the significantly deceased phagocytosis ability and LAP related proteins, with lowest at 24 h after SAH. SIRT2 inhibition significantly improved LAP function in OxyHb stimulated microglia, but its effect was reversed by a NRF2 inhibitor; (4) in vitro mechanistic experiments showed SIRT2 impaired NRF2 nuclear translocation through acetylation, and reduced subsequent CD36 expressions transcriptionally, leading to inhibiting the LAP form of microglia phagocytosis. SIRT2 inhibition significantly improved the microglia LAP after SAH. Taken together, these findings not only elucidate the role of SIRT2 in CNS immune regulation, but also provide a potential therapeutic target for treating secondary brain injury after SAH. As a NAD⁺-dependent deacetylase, SIRT2 is widely involved in the procession of oxidative stress, cell cycle regulation, metabolism, and neurodegenerative disease [23–25]. In rodent models, SIRT2 inhibition resulted in neuroprotective effects in ischemic stroke [26] and anti-neuroinflammatory after TBI [27]. Consistently, the present study showed the therapeutic benefits of SIRT2 inhibition on short-term and long-term neurological outcomes, brain edema and BBB preservation after SAH in rats. Previous studies demonstrate that SIRT2 inhibition can alleviated neuroinflammation by reducing microglial mitophagy and pyroptosis as well as promoting M2 microglial polarization after SAH in mice [10, 11]. We further investigated the role of SIRT2 in microglial phagocytic function and its underlying mechanisms using an in vitro subarachnoid hemorrhage (SAH) model with primary microglia cultures. Microglia, as the main innate immune cells of the CNS, have the ability to clear exogenous blood components, necrotic cells and oxidative metabolites, and play a core role in maintaining tissue homeostasis and promoting injury repair [28, 29]. Recent studies found that when microglia deal with large “bulk cargo”, such as hemoglobin or iron deposition, they rely more on LAP rather than the canonical autophagy [30, 31]. Although LAP also depends on the membrane assembly of LC3, it does not involve canonical autophagy initiation complexes such as ULK1. Its characteristic molecules include Rubicon and NOX2 [32, 33]. In this study, we observed that the phagocytic ability of microglia decreased significantly within 24 h after SAH, accompanied by the downregulation of LAP-related molecules such as Rubicon, NOX2, and LC3, suggesting that LAP function was inhibited. This result is consistent with our previous study that the phagocytic ability of microglia decreased in the early of SAH [7]. This indicates that the activation and maintenance of LAP have important regulatory significance on the pathological process. Further mechanistic studies have shown that inhibiting SIRT2 not only restores the phagocytic ability of microglia, but also significantly upregulates the expression of LAP-related proteins, enhances the co-localization of LC3 and pHrodo, and restores the typical LAPosome structure observed under TEM. These results suggest that SIRT2 is a negative regulator of LAP, and its inhibition may relieve LAP inhibition and enhance microglial mediated- clearance of blood clots, thereby alleviating the damage caused by the accumulation of hemorrhagic components in brain tissue. It is worth noting that the canonical autophagy marker ULK1 did not show significant changes under different experimental conditions, which further supports that the regulatory effect of SIRT2 is specifically located in the LAP process. NRF2, as a core transcription factor for oxidative stress response, has also been found to be involved in the regulation of various immune and phagocytic functions [34, 35]. Feng et al. proposed [36] that NRF2 participates in the maintenance of immune homeostasis by regulating ROS metabolism and iron homeostasis. In the intracerebral hemorrhage (ICH) model [37], NRF2 activation enhanced the clearance of hemoglobin by microglia and alleviated neuroinflammation. In this study, we confirmed through proteomics, molecular docking and co-immunoprecipitation that SIRT2 can directly inhibit the nuclear translocation and transcriptional activity of NRF2 through deacetylation, accompanied by upregulation of its target genes such as Hmox1 and Gclm. This finding not only reveals the regulatory role of the SIRT2-NRF2 axis in the immune clearance process of SAH, but also suggests that acetylation modification is an important mechanism for regulating NRF2 activity. Reduced SIRT2 deacetylase activity by AK7 in microglia can also affect the stability and activity of other proteins, including transcription factors that regulate the SIRT2 gene itself, leading to downregulation of SIRT2 level. Consistently, SIRT2 inhibition by AK7, were significantly enhanced the NRF2 positive and CD36 positive microglial in piriform cortex, a brain region vulnerable to the blood and inflammatory products released after SAH, supporting the presence and function of the microglial SIRT2/NRF2/CD36 pathway in the rat model of SAH. As a classic “eat me” signal receptor, CD36 is widely involved in the recognition and clearance of cell debris, oxidized lipids and apoptotic cells. In various disease such as atherosclerosis, Alzheimer’s disease, and ischemic stroke, it has been shown that CD36 function is closely related to the degree of inflammation and disease progression [38–40]. In this study, we utilized the JASPAR database for promoter prediction, combined with protein detection and functional intervention experiments, to confirm that NRF2 transcriptionally activates CD36 expression and plays a critical role in LAP. When NRF2 was inhibited by ML385, both CD36 upregulation and the enhancement of LAP were reversed, further supporting its role as a core effector of NRF2-mediated LAP. As a core molecule in the LAP pathway, Rubicon plays an irreplaceable role in the execution of LAP by stabilizing the NOX2 complex, regulating ROS generation, and LC3 recruitment [41, 42]. We found that knockdown of Rubicon not only significantly weakened the LAP capacity of microglia but also antagonized the phagocytic enhancement effect of SIRT2 inhibition. TEM result further showed that the Rubicon-positive monolayer membrane phagosome structure was significantly enhanced in the SIRT2 inhibition group, suggesting that the SIRT2/NRF2/CD36 signaling axis may achieve multi-node regulation of the entire LAP process by regulating the expression, localization, and recruitment of Rubicon. Furthermore, we observed that SIRT2 inhibition improved neurological function after SAH in rats, including improvements in motor coordination and spatial learning and memory. Although this behavioral improvement may be influenced by multiple mechanisms, the current results suggest that part of its effect may be due to enhancing LAP function in microglia and promoting the clearance of harmful metabolites. Intranasal delivery of the SIRT2 inhibitor enhanced microglial phagocytic phenotypes associated with an anti-inflammatory profile, potentially contributing to improved neuronal survival in the hippocampus. Although this study did not directly examine long-term neuronal survival in the piriform cortex, our supplementary results (Fig. S7) showed the presence and function of the SIRT2/NRF2/CD36 pathway in piriform cortical microglia in SAH rats. Given that SIRT2 inhibition enhances the phagocytic capacity of microglia, we speculate that its neuroprotective effects in the piriform cortex may parallel those observed in the CA1 region. This finding not only supports the biological significance of SIRT2 regulating LAP function at the mechanistic level, but also provides a theoretical basis for future intervention strategies targeting SIRT2 to regulate immune clearance to improve neurological function after SAH. To be noted, microglial SIRT2 deficiency has been shown to aggravate cognitive decline and amyloid pathology in Alzheimer’s disease [23]. The discrepancy may primarily stem from differences in the pathological context. Alzheimer’s disease is a chronic progressive disease, and SIRT2 deficiency disrupts long-term microenvironmental homeostasis; in contrast, SAH is an acute event, and the massive accumulation of blood components leads to an acute inflammatory response. In the context of SAH, SIRT2 inhibition can improve prognosis by enhancing microglial phagocytosis and clearance of toxic blood components. Therefore, the role of SIRT2 may be different in different disease settings. There are several limitations in this study. First, the mechanism underlying the neurobehavior benefits of SIRT2 inhibition after SAH may involves additional signaling pathways beyond LAP, as well as other cell types such as oligodendrocyte. Second, NRF2 regulation of CD36 lacks direct verification by ChIP-qPCR or ChIP-seq. Third, the existence of cross-regulation between the LAP pathway and canonical phagocytic pathways (such as TREM2 and NLRP3) remains unclear. Future studies could combine transcriptome and chromatin modification profiling to further elucidate the epigenetic regulatory of SIRT2 in regulating LAP, thereby expanding its application as a therapeutic target in hemorrhagic brain disorders, such as ICH or TBI. Conclusion SIRT2 suppresses microglial LAP by deacetylating NRF2, thereby impairing its nuclear translocation and reducing transcriptional expression of CD36 subsequently. Inhibiting SIRT2 may effectively enhance microglial LAP function, promote blood clearance and improve neurological prognosis after SAH (Fig. 8). Schematic diagram of our study. SIRT2 modified NRF2 by deacetylation and inhibited its entry into the nucleus, affecting the transcription of downstream CD36, thereby reducing LAP in microglia Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Acknowledgements The authors thank all the other members in their laboratory for their insight and technical support. Abbreviations Subarachnoid hemorrhage Sprague-Dawley Sirtuin 2 LC3-associated phagocytosis Second brain injury Central nervous system Nuclear factor erythroid 2–related factor 2 Common carotid artery External carotid artery Internal carotid artery Middle cerebral artery Oxygenated hemoglobin Cell Counting Kit-8 Lactate dehydrogenase Blood-brain barrier Trichloroacetic acid Tandem mass tag Oxyhemoglobin Phosphate-buffered saline Transmission electron micrograph Bicinchoninic acid Enzyme-linked immunosorbent assay Fluoro-Jade C Flow cytometry Revolutions per minute Reactive oxygen species Alzheimer’s disease Traumatic brain injury Intracerebral hemorrhage Authors’ contributions The work was designed by CH, Hang, Lei Huang and JH, Zhang. The experiments were performed by Bin Sheng, XX, Chen, Tao Tao and JQ, Sun.Wei Li, Zheng Peng, XJ Li, Qian Yu and YP Ling collected and analyzed the data. P Sherchan, JJ. Flores and JP Tang, JHZ have drafted and substantively revised the work. ZX Zhou, and LY Wu made great contributions to the revision of the manuscript. All authors read and approved the final manuscript. Funding This work was supported by grants from the National Institutes of Health. (NIH NS 117179), and the National Natural Science Foundation of China (82130037 and 82301485). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate All animal experiments in this study have been approved by the Institutional Animal Care and Use Committee of Loma Linda University in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. Competing interests The authors declare no competing interests. Footnotes The original online version of this article was revised due to update the figure 4H. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Bin Sheng, Xiangxin Chen, Tao tao and Jiaqing Sun contributed equally to this work. Change history 6/29/2026 The original online version of this article was revised due to update the figure 4H. Change history 7/7/2026 A Correction to this paper has been published: 10.1186/s12974-026-03943-8 Contributor Information Lei Huang, Email: lhuang@llu.edu. Chunhua Hang, Email: hang_neurosurgery@163.com. John H. Zhang, Email: johnzhang3910@yahoo.com References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Data Availability Statement No datasets were generated or analysed during the current study.